Sam Chun Dang Pharm. Co. Ltd - Asset Resilience Ratio
Sam Chun Dang Pharm. Co. Ltd (000250) has an Asset Resilience Ratio of 6.87% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 000250 net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2025)
This chart shows how Sam Chun Dang Pharm. Co. Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Sam Chun Dang Pharm. Co. Ltd.
Liquid Assets Composition Over Time
This chart breaks down Sam Chun Dang Pharm. Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore 000250 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩39.51 Billion | 6.87% |
| Total Liquid Assets | ₩39.51 Billion | 6.87% |
Asset Resilience Insights
- Limited Liquidity: Sam Chun Dang Pharm. Co. Ltd maintains only 6.87% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Sam Chun Dang Pharm. Co. Ltd Industry Peers by Asset Resilience Ratio
Compare Sam Chun Dang Pharm. Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Theragen Etex Co.Ltd
KQ:066700 |
Pharmaceuticals | 0.68% |
|
ST Pharm Co.Ltd
KQ:237690 |
Pharmaceuticals | 7.72% |
|
NatureCell Co.Ltd
KQ:007390 |
Pharmaceuticals | 0.00% |
|
Oscotec Inc
KQ:039200 |
Pharmaceuticals | 65.38% |
|
Mezzion Pharma Co.Ltd
KQ:140410 |
Pharmaceuticals | 13.09% |
|
Komipharm International Co. Ltd
KQ:041960 |
Pharmaceuticals | 0.00% |
|
Caregen Co.Ltd
KQ:214370 |
Pharmaceuticals | 4.58% |
|
Aprogen Healthcare & Games Inc
KQ:109960 |
Pharmaceuticals | 6.55% |
Annual Asset Resilience Ratio for Sam Chun Dang Pharm. Co. Ltd (2012–2025)
The table below shows the annual Asset Resilience Ratio data for Sam Chun Dang Pharm. Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 5.90% | ₩33.11 Billion ≈ $22.44 Million |
₩561.23 Billion ≈ $380.34 Million |
-0.90pp |
| 2024-12-31 | 6.80% | ₩35.33 Billion ≈ $23.94 Million |
₩519.77 Billion ≈ $352.24 Million |
-6.76pp |
| 2023-12-31 | 13.56% | ₩55.32 Billion ≈ $37.49 Million |
₩408.02 Billion ≈ $276.51 Million |
-9.57pp |
| 2022-12-31 | 23.13% | ₩86.23 Billion ≈ $58.44 Million |
₩372.79 Billion ≈ $252.64 Million |
-4.90pp |
| 2021-12-31 | 28.03% | ₩97.00 Billion ≈ $65.73 Million |
₩346.00 Billion ≈ $234.48 Million |
-2.53pp |
| 2020-12-31 | 30.56% | ₩96.91 Billion ≈ $65.68 Million |
₩317.08 Billion ≈ $214.88 Million |
-3.65pp |
| 2019-12-31 | 34.22% | ₩99.28 Billion ≈ $67.28 Million |
₩290.15 Billion ≈ $196.63 Million |
+3.62pp |
| 2018-12-31 | 30.60% | ₩79.91 Billion ≈ $54.15 Million |
₩261.16 Billion ≈ $176.98 Million |
+3.62pp |
| 2017-12-31 | 26.98% | ₩62.09 Billion ≈ $42.07 Million |
₩230.14 Billion ≈ $155.96 Million |
+2.41pp |
| 2016-12-31 | 24.56% | ₩50.38 Billion ≈ $34.14 Million |
₩205.11 Billion ≈ $139.00 Million |
+22.46pp |
| 2015-12-31 | 2.10% | ₩3.88 Billion ≈ $2.63 Million |
₩184.26 Billion ≈ $124.87 Million |
-3.58pp |
| 2014-12-31 | 5.68% | ₩9.80 Billion ≈ $6.64 Million |
₩172.49 Billion ≈ $116.89 Million |
+2.09pp |
| 2013-12-31 | 3.59% | ₩5.58 Billion ≈ $3.78 Million |
₩155.38 Billion ≈ $105.30 Million |
-0.80pp |
| 2012-12-31 | 4.39% | ₩5.36 Billion ≈ $3.63 Million |
₩122.08 Billion ≈ $82.73 Million |
-- |
About Sam Chun Dang Pharm. Co. Ltd
Sam Chun Dang Pharm. Co., Ltd manufactures, distributes, imports, and exports pharmaceuticals in South Korea. It provides ophthalmology, cardiovascular, endocrinology, antibacterial, anti-fungal, antiviral, respiratory, anti-inflammatory, antihistamine, and musculoskeletal products, as well as vitamins and gastro intestine products. The company was founded in 1943 and is headquartered in Seoul, S… Read more